Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : RETA save search
TCBI NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Texas Capital Bancshares, Inc.
Published: 2023-05-29 (Crawled : 09:00) - prnewswire.com
TCBI | News | $56.01 0.16% 0.16% 540K
|
Finance
| Email alert
Add to watchlist
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
| Email alert
Add to watchlist
PHAT NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Phathom Pharmaceuticals, Inc.
Published: 2023-05-29 (Crawled : 09:00) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
| Email alert
Add to watchlist
PHAT | $9.5 -3.06% -3.16% 420K
|
Health Technology
| Email alert
Add to watchlist
RETA NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Reata Pharmaceuticals, Inc.
Published: 2023-05-29 (Crawled : 09:00) - prnewswire.com
TCBI | News | $56.01 0.16% 0.16% 540K
|
Finance
| Email alert
Add to watchlist
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
| Email alert
Add to watchlist
RH NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of RH
Published: 2023-05-29 (Crawled : 09:00) - prnewswire.com
TCBI | News | $56.01 0.16% 0.16% 540K
|
Finance
| Email alert
Add to watchlist
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
| Email alert
Add to watchlist
RETA INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Reata Pharmaceuticals, Inc.
Published: 2023-05-26 (Crawled : 02:00) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.0%
H: 1.85%
C: -0.25%
PHAT | $9.5 -3.06% -3.16% 420K
|
Health Technology
|
| O: 0.26%
H: 1.96%
C: 0.09%
FRG | $29.88 0.1% 0.1% 0
|
Commercial Services
|
| O: 0.17%
H: 0.21%
C: -0.15%
RH INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of RH
Published: 2023-05-26 (Crawled : 02:00) - prnewswire.com
TCBI | News | $56.01 0.16% 0.16% 540K
|
Finance
|
| O: -0.06%
H: 0.51%
C: 0.39%
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.0%
H: 1.85%
C: -0.25%
TCBI INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Texas Capital Bancshares, Inc.
Published: 2023-05-26 (Crawled : 02:00) - prnewswire.com
TCBI | News | $56.01 0.16% 0.16% 540K
|
Finance
|
| O: -0.06%
H: 0.51%
C: 0.39%
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.0%
H: 1.85%
C: -0.25%
CNS Pharmaceuticals (NASDAQ:CNSP) Achieves Over 50% Completion of Enrollment in Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2023-05-25 (Crawled : 20:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -0.18%
H: 0.79%
C: -2.78%
CNSP | $0.1975 -3.38% -3.49% 130K
|
Health Technology
|
| O: -4.52%
H: 6.84%
C: 4.74%
berubicin treatment pharmaceuticals glioblastoma study
Reata Pharmaceuticals, Inc. Announces First Quarter 2023 Financial Results and Provides an Update on Operational Progress and Clinical Development Programs
Published: 2023-05-10 (Crawled : 12:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -15.06%
H: 3.04%
C: 0.98%
update financial results
Over 100 Patients Now Enrolled in CNS Pharmaceuticals’ (NASDAQ: CNSP) Potentially Pivotal Study Evaluating Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2023-04-10 (Crawled : 16:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -1.23%
H: 1.81%
C: 1.25%
CNSP | $0.1975 -3.38% -3.49% 130K
|
Health Technology
|
| O: -4.79%
H: 8.16%
C: 4.9%
berubicin treatment 100 glioblastoma study
CNS Pharmaceuticals Receives Approval from Competent Authority and Central Ethics Committee in Italy for Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Published: 2023-04-06 (Crawled : 14:20) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.79%
H: 0.86%
C: 0.6%
CNSP | $0.1975 -3.38% -3.49% 130K
|
Health Technology
|
| O: 53.58%
H: 6.02%
C: -43.6%
approval berubicin treatment pharmaceuticals global trial
REATA PHARMACEUTICALS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC Investigates the Officers and Directors of Reata Pharmaceuticals, Inc. - RETA
Published: 2023-03-18 (Crawled : 08:20) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
| Email alert
Add to watchlist
CTLT | $55.8 -0.29% 0.0% 1M
|
Health Technology
| Email alert
Add to watchlist
KRNT | $15.5 -0.32% -0.32% 160K
|
Producer Manufacturing
| Email alert
Add to watchlist
pharmaceuticals initiated
CNS Pharmaceuticals Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM with First Patient Enrolled in Switzerland
Published: 2023-03-09 (Crawled : 14:20) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -2.68%
H: 5.52%
C: 3.54%
CNSP | $0.1975 -3.38% -3.49% 130K
|
Health Technology
|
| O: -2.72%
H: 4.3%
C: -5.59%
treatment ongoing pharmaceuticals global trial berubicin momentum switzerland
Reata Pharmaceuticals Announces Participation in the Barclays Global Healthcare Conference
Published: 2023-03-06 (Crawled : 13:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -0.96%
H: 1.07%
C: -1.66%
pharmaceuticals global conference
Reata Pharmaceuticals Announces FDA Approval of SKYCLARYS™ (Omavaloxolone), the First and Only Drug Indicated for Patients with Friedreich’s Ataxia
Published: 2023-02-28 (Crawled : 00:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.49%
H: 25.61%
C: 0.55%
fda pharmaceuticals drug approval friedreich’s ataxia
CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Published: 2023-02-07 (Crawled : 14:00) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.0%
H: 0.64%
C: -0.91%
CNSP | $0.1975 -3.38% -3.49% 130K
|
Health Technology
|
| O: -1.49%
H: 5.19%
C: -6.49%
treatment ongoing pharmaceuticals global trial berubicin
CNS Pharmaceuticals Announces Investigator-Initiated Phase 1b/2 Trial to be Conducted at the Pomeranian Medical University in Poland
Published: 2023-01-12 (Crawled : 14:00) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -0.22%
H: 3.54%
C: 2.81%
CNSP | $0.1975 -3.38% -3.49% 130K
|
Health Technology
|
| O: -2.21%
H: 5.66%
C: -6.04%
pharmaceuticals medical trial phase 2b
CNS Pharmaceuticals Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for the Treatment of Recurrent Glioblastoma Multiforme (GBM)
Published: 2022-12-08 (Crawled : 15:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.34%
H: 1.98%
C: -1.85%
CNSP | $0.1975 -3.38% -3.49% 130K
|
Health Technology
|
| O: 2.92%
H: 0.03%
C: -3.66%
treatment ongoing pharmaceuticals trial berubicin glioblastoma
Reata Pharmaceuticals Announces Participation in the Guggenheim 2022 Immunology and Neurology Conference and the Stifel 2022 Healthcare Conference
Published: 2022-11-10 (Crawled : 00:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 4.31%
H: 1.2%
C: -5.49%
pharmaceuticals conference immunology
Extremely Robust COVID-19 Clinical Trial Pipeline With 420+ Key Companies Expected to Change the Pace of the COVID-19 Treatment
Published: 2022-11-08 (Crawled : 16:00) - prnewswire.com
XNCR | $18.98 -0.47% -0.47% 470K
|
Health Technology
|
| O: 0.3%
H: 12.8%
C: 8.43%
VRNA | $16.1 -1.83% -1.86% 490K
|
Health Technology
|
| O: 1.35%
H: 2.31%
C: 1.09%
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 3.15%
H: 18.92%
C: 11.92%
KNSA | $16.88 -0.41% -0.41% 410K
|
Health Technology
|
| O: -0.13%
H: 0.26%
C: -3.81%
covid-19 treatment companies change expected trial
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.